Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 52 clinical trials
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer

in patients presenting with locally advanced breast cancer.

axillary lymph node dissection
sentinel lymph node biopsy
advanced breast cancer
sentinel node
locally advanced breast cancer
  • 30 views
  • 07 Oct, 2022
  • 8 locations
Novel MRI-Guided Ultrasound Stimulated Microbubble Radiation Treatment for Patients With Chest-wall and Locally-Advanced Breast Cancer (USmBRT-B)

The objective of this study is to demonstrate the feasibility of novel MRI-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam radiotherapy delivered using a LINAC (linear accelerator) radiation therapy device.

advanced breast cancer
carcinoma
breast cancer staging
  • 0 views
  • 04 Oct, 2022
  • 1 location
A Phase 1 Study of HRS8807 Monotherapy and in Combination With SHR6390 in Subjects With ER-Positive HER2-Negative Metastatic or Locally Advanced Breast Cancer

The study is to assess safety and tolerability of HRS8807 monotherapy and in combination with SHR6390 in subjects with metastatic or locally advanced breast cancer in order to estimate the Dose

  • 0 views
  • 21 Nov, 2021
  • 1 location
Prognostic Impact of the Neutrophil/Lymphocyte Ratio (NLR) in the Treatment of First-line Metastatic or Locally Advanced Breast Cancer Treated With CDK4/6 Inhibitor. (PEPSI)

The impact of the inflammatory microenvironment in predicting the benefit of a CDK4/6 inhibitor in the treatment of locally advanced or first line metastatic breast cancer has not yet been studied. We propose a multicenter prospective study to confirm the prognostic value of pre-therapy NLR on progression-free survival of patients …

hormone therapy
measurable disease
her2/neu-negative breast cancer
advanced breast cancer
HER2
  • 0 views
  • 15 Jun, 2022
  • 1 location
Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

This study aimed to evaluate the Pyrotinib in combination with albumin-bound paclitaxel and trastuzumab to neoadjuvant therapy efficacy and safety of Her2-positive early or locally advanced

immunohistochemistry
measurable disease
trastuzumab
advanced breast cancer
paclitaxel
  • 0 views
  • 28 Oct, 2022
  • 1 location
Three Fraction Radiation to Induce Immuno-Oncologic Response

Patients with high risk breast cancers (any locally advanced breast cancer patient defined as Stages IIB-III [excluding inflammatory breast cancer] with stage IIA being eligible for triple

  • 0 views
  • 18 Aug, 2021
  • 1 location
The p53 Breast Cancer Trial (p53b)

disease, and treated with dose-dense cyclphosphamide. Furthermore, patients included are stratified based on tumor stage; i.e. locally advanced breast cancer (M0 disease) or metastatic breast cancer (M1

  • 28 views
  • 04 Oct, 2022
  • 4 locations
Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

cyclophosphamide followed by docetaxel in HR positive and HER2-low-expressing early or locally advanced breast cancer.

advanced breast cancer
cyclophosphamide
erbb2
carcinoma
inflammatory breast cancer
  • 0 views
  • 24 Mar, 2022
  • 1 location
TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer (TIBET)

This is a multicenter phase 2 study evaluating the efficacy and safety of trifluridine/tipiracil in women with metastatic or locally advanced breast cancer not amenable to curative treatment by

taxane
capecitabine
advanced breast cancer
HER2
locally advanced breast cancer
  • 0 views
  • 17 Mar, 2022
  • 10 locations
Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

The aim of the present study is to evaluate the efficacy and safety of palbociclib plus fulvestrant after failure of a combined treatment of hormonal therapy (aromatase inhibitor or tamoxifen LHRHa) plus a CDK4/6 inhibitor, in women with HR+ and HER2- LABC or MBC. Primary endpoint: To assess the clinical …

hormone therapy
measurable disease
tamoxifen
human epidermal growth factor
endocrine therapy
  • 1 views
  • 02 Mar, 2022
  • 3 locations